4//SEC Filing
Melincoff Gwen A 4
Accession 0001104659-22-098944
CIK 0001006281other
Filed
Sep 8, 8:00 PM ET
Accepted
Sep 9, 5:01 PM ET
Size
6.0 KB
Accession
0001104659-22-098944
Insider Transaction Report
Form 4
Melincoff Gwen A
Director
Transactions
- Award
Stock Options (Right to Buy)
2022-09-07+50,000→ 50,000 totalExercise: $1.03Exp: 2032-09-07→ Common Stock (50,000 underlying)
Footnotes (2)
- [F1]The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.
- [F2]Does not include options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030.
Documents
Issuer
Protalix BioTherapeutics, Inc.
CIK 0001006281
Entity typeother
Related Parties
1- filerCIK 0001614890
Filing Metadata
- Form type
- 4
- Filed
- Sep 8, 8:00 PM ET
- Accepted
- Sep 9, 5:01 PM ET
- Size
- 6.0 KB